Article

Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression

2025-03-31

Abstract excerpt

<title>Abstract</title> <p>Pirtobrutinib is a reversible Bruton’s tyrosine kinase (BTK) inhibitor that has shown efficacy for patients with chronic lymphocytic leukemia (CLL) in BRUIN trial. These patients were previously treated with covalent BTK inhibitor (cBTKi) and either discontinued cBTKi or had disease progression during therapy. As a result, some patients had wild-type BTK while others had mutant BTK (mos...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a31143ab-c44e-5ff4-b698-caaa8060593a
DOI: 10.21203/rs.3.rs-6249480/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progressionDOI 10.21203/rs.3.rs-6249480/v1Read

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.Semantic proximity Read

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity Read

Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib.Semantic proximity Read

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.Semantic proximity Read

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted TherapySemantic proximity Read

BTK inhibitors in CLL: second-generation drugs and beyond.Semantic proximity Read

Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.Semantic proximity Read

Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLLSemantic proximity Read

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity Read

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Semantic proximity Read

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.Semantic proximity Read

BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.Semantic proximity Read